The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO).
Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email email@example.com or call 312-355-5112.
BMS CA209-77T: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Sponsor: Bristol-Myers Squibb
Principal Investigator: Lawrence Feldman, MD